Skip to content
About Us
Axon Therapies, a private medtech company, was founded to bring more treatment options to heart failure patients, especially those with preserved ejection fraction.

“We think there is a different approach to treating Heart Failure that could fundamentally change outcomes for patients, and we are deeply committed to seeing that vision through to reality.”

Chad Hoskins,
President & CEO
We developed the SAVM procedure, a simple and novel approach to modulating the body’s sympathetic nervous system to restore balance in the circulatory system, with the goal of improving functional capacity and quality of life for heart failure patients.

Pioneering groundbreaking technology is never easy, but we have built a team of innovators, with the passion to improve the lives of heart failure patients globally. And with our clinical partners, that is just what we are on the path to doing.

Leadership

Chad
Chad Hoskins
Chief Executive Officer
BIO
Howard Levin
Howard Levin, MD
Chief Medical Officer
BIO
PJ Iranitalab
PJ Iranitalab
VP of Engineering
BIO
Matt Stark
Matt Stark
VP of Clinical & Regulatory Affairs
BIO

Advisors

Sanjiv Shah, MD
Northwestern University
BIO
Marat Fudim, MD
Duke University
BIO
Barry Borlaug, MD
Mayo Clinic
BIO
Sheldon Litwin, MD
Medical University of South Carolina
BIO
Vivek Reddy, MD
Mt. Sinai
BIO

Investors

Our work is supported by leading financial investors as well as a confidential strategic investor.

The Axon Ablation System is an investigational device and is not currently approved for clinical use in any geography.

CAUTION – Investigational Device. Limited by Federal (or United States) law to Investigational Use.

 ClinicalTrials.gov identifier:  NCT04592445

©2022 Axon Therapies Inc. All rights reserved. Axon is a trademark of Axon Therapies, Inc.
Patent information